Purpose: To determine if levels of the glycocalyx membrane mucins, MUC1 and MUC16, and the secreted goblet cell mucin MUC5AC are altered in conjunctival cells and tears of postmenopausal women presenting with a history of non-Sjögren dry eye and if mucin levels correlate with dry eye clinical diagnostic data.
D ry eye is a multifactorial disease of the ocular surface, prevalent in postmenopausal women, that results in damage to the ocular surface epithelium. 1 The apical membrane surface of the corneal and conjunctival epithelium is covered by a glycocalyx that forms the interface with the epithelium and the tear fluid. The glycocalyx is rich in membrane-tethered mucins, including MUC1, MUC4, and MUC16, 2 the ectodomains of which are constitutively released into the tear film. 3 Also within the tear fluid, the goblet cellderived secreted mucin MUC5AC is present. Both mucin types play a role in epithelial surface protection. Secreted mucins clear the ocular surface of debris, and membrane mucins form a glycocalyx barrier to pathogen and dye penetrance. 2, 4 Because dry eye disease is prevalent in postmenopausal women, and given the protective role of mucins at the ocular surface, this study focused on the comparison of mucin levels in postmenopausal women with or without significant symptoms of dry eye.
Ocular surface damage in dry eye is detected by a battery of tests, including ocular surface staining using the dyes rose bengal, lissamine green, and/or sodium fluorescein, measurement of tear break-up time, tear secretion (eg, using the Schirmer test), and symptom assessment. To date, the only insight regarding the correlation of mucin expression with such clinical endpoints is the in vitro finding that the membrane mucin MUC16, along with its O-glycans, plays an important role as the barrier to rose bengal penetrance. 4, 5 Alterations in ocular surface mucins in dry eye have been previously reported. A decrease in goblet cell-derived MUC5AC in tears and impression cytology samples from patients with Sjögren syndrome, as compared with agematched controls, has been demonstrated, 6 and a decrease in tear MUC5AC, as measured by immunolocalization of MUC5AC antibody to tears collected by Schirmer strip in undifferentiated keratoconjunctivitis sicca (KCS), has been reported. 7 Alteration in membrane mucins in dry eye also has been reported. Several immunohistochemical studies of membrane mucin distribution on apical conjunctival cells obtained by impression cytology have shown alterations in localization patterns with dry eye. [8] [9] [10] Binding of an antibody to a carbohydrate epitope on MUC16 to apical surfaces of conjunctiva (using antibody H185) has been shown to be reduced in patients with non-Sjögren dry eye and is correlated with disease severity. 9 An increase in the frequency of expression of a shorter secreted form of MUC1, the result of a gene splice variant, has also been reported for dry eye. 11, 12 These studies are, however, limited in that they provide only semiquantitative immunohistochemical data and/or relatively few patients.
Taken together, these studies implicate alterations in epithelial surface and/or goblet cell-derived mucins in the pathophysiology of dry eye. To date, there has not been a study using sufficient numbers of subjects in which mucin messenger RNA (mRNA) and mucin protein (both epithelial cell-associated mucins and soluble tear mucins) content is quantified and correlated with disease status. Such a study would provide valuable information on both changes in expression with disease and release of mucins into tears.
Thus, the purpose of this study was to compare membrane-bound (MUC1 and MUC16) and soluble (MU-C5AC) mucin levels and mucin mRNA expression in a group of postmenopausal women with a history of dry eye symptoms with that of age-matched postmenopausal women, and to correlate mucin level data with clinical diagnostic data obtained from the subjects.
MATERIALS AND METHODS

Subject Selection
This study was conducted in compliance with good clinical practice, Institutional Review Board regulations, informed consent regulations, and the tenets of the Declaration of Helsinki. Women with natural menopause and non-Sjögren dry eye, aged 45 years or older, and of any race were recruited from a single center. Subjects were considered postmenopausal if they had had no menses for at least 12 months. Subjects were considered as having a history of dry eye based on the following: (1) documented diagnosis in medical charts made by a medical care provider $6 months before study visit and (2) a documented history for $3 months of symptoms of ocular discomfort consistent with dry eyes (burning, stinging, blurring, gritty, dry). In addition to these 2 criteria, subjects included in the dry eye group must have answered ''yes'' to the question, ''Are you currently using or have desire to use artificial tears, ocular lubricants, or rewetting drops?'' Subjects with no medical diagnosis of dry eye, no ocular discomfort consistent with dry eye, no use of artificial tears, lubricants, or rewetting drops, and no autoimmune disorders were classified as healthy (non-dry eye) subjects.
Exclusion criteria for all subjects included the following: younger than age 45 years, childbearing potential or menses within the past 12 months, surgical removal of ovaries with or without fallopian tube, removal of uterus or endometrial ablation, a medical diagnosis of diabetes and/or autoimmune connective tissue disease (including lupus erythematosus, mixed connective tissue, scleroderma, rheumatoid arthritis, and/or Sjögren syndrome), keratorefractive ocular laser procedures, use of topical ocular medications, corneal surgery or other surgery to the corneal surface, punctal cauterization, or current punctal plugs. A history of plug placement was allowed if there was documentation in the medical chart of dislodgement or removal of the plug $30 days before the study visit. Also excluded were patients with a history of contact lens wear within the past 6 months or intraocular laser procedures within 1 year of the study visit.
Clinical Assessment
Once enrolled in the study, on the day of collection, subjects responded to a dry eye symptom questionnaire (DESQ) and underwent routine clinical work-up to further characterize disease presence and severity, including assessment of tear break-up time and ocular surface staining, based on the National Eye Institute/Industry workshop method 13 (fluorescein and lissamine green), tear meniscus height, conjunctival redness, photophobia questionnaire [consisting of 1 question, ''How often during the past 24 hours were you noticeably more sensitive to light than normal for you?''; the answer was scaled from 0 (none) to 4 (continuously)].
In addition, symptoms were assessed using a DESQ consisting of the following 7 questions, scored 0 (not at all) to 4 (6 or more times): 1. How often during the past 24 hours were your eyes noticeably burning more than normal for you? 2. How often during the past 24 hours were your eyes noticeably stinging more than normal for you? 3. How often during the past 24 hours were your eyes noticeably more blurry than normal for you? 4. How often during the past 24 hours were your eyes noticeably more gritty than normal for you? 5. How often during the past 24 hours were your eyes more dry than normal for you? 6. How often during the past 24 hours did your eyes experience scratchiness? 7. How often during the past 24 hours did you experience foreign body sensation?
Sample Collection and Processing
Collection of tears with a capillary tube took place immediately after best-corrected visual acuity was measured and after slit-lamp biomicroscopy. Collection of tears using a tear wash took place a minimum of 30 minutes after capillary tear collection. Impression cytology was performed immediately after tear wash.
Using a graduated, disposable, 5-mL microcapillary tube (Wiretol-Micropipettes; Drummond Scientific Co., Broomall, PA), up to 5 mL of tears per eye were collected from the inferior temporal tear meniscus of each participant, without corneal anesthesia, taking care to ensure that the lid margin and corneal surface were not touched. Tears from both eyes were pooled. For tear wash collection, starting with the right eye, 60 mL of sterile physiological saline (0.9% NaCl) (Minims; Chauvin Pharmaceuticals, Romford, Essex, United Kingdom) was applied to the superior bulbar region of the unanesthetized ocular surface using a sterile micropipette. Participants were asked to rotate their eyes without blinking, and then the wash was collected from the inferior fornix using the micropipette. The same procedure was repeated with the left eye. Both tear washes were pooled together. All tear samples were immediately placed on dry ice until transfer to 280°C for storage.
Conjunctival epithelial cells were collected by impression cytology from each eye using sterile Millipore MF membranes (pore size, 0.45 mM). Two drops of a topical anesthetic (Alcaine; Alcon Research, Fort Worth, TX), in doses administered 60 seconds apart, were applied to the right eye. Fifteen seconds after the second drop of anesthetic, the subject was instructed to hold the gaze down to expose the superior conjunctiva. One piece of filter paper was placed on the superior region of the conjunctiva and then removed with blunt forceps and placed in a sterile, prelabeled, 2-mL, capped, polypropylene centrifuge tube containing 1 mL of RLT RNA isolation buffer (Qiagen, Valencia, CA) containing 0.01% b-mercaptoethanol. The same procedure then was performed on the temporal conjunctiva, and the filter paper was placed in the same tube as the superior sample. Anesthesia and impression cytology of the left eye were then performed as described for the right eye, with the exception that the 2 filter papers were placed in an empty, sterile, 2-mL, capped, polypropylene centrifuge tube, for subsequent protein extraction. All samples were immediately placed on dry ice and then transferred to 280°C for storage until processing.
RNA Isolation From Conjunctival Impression Cytology Samples and Reverse Transcription
Tubes containing 1 mL of RLT buffer (Qiagen) and 2 impression cytology samples were allowed to thaw at room temperature and then were vortexed for 30 seconds. Impression cytology membranes were removed using a 21-gauge needle, and samples were passed through a 21-gauge needle 10 times. Extraction of total RNA proceeded according to the manufacturer's directions (RNeasy Minikit; Qiagen). The DNase step, as recommended, was performed. The final isolation step was conducted with 40 mL of ribonuclease-free water.
Protein Isolation From Conjunctival Impression Cytology Samples
Left eye impression cytology samples were used to isolate protein. Filter papers were placed cell side up on small glass plates, and 5 mL of extraction buffer [2% sodium dodecyl sulfate; 13 complete protease inhibitor cocktail (Roche, Mannheim, Germany)] was placed on each. Using a steel scalpel blade, each membrane was cut into small pieces, which were placed in 600-mL capped polypropylene centrifuge tubes and covered with an additional 50 mL of extraction buffer. Tubes were vortexed and then heated at 95°C for 10 minutes. Tubes were centrifuged at 12,000 g for 6 minutes, and the protein extract was collected and transferred to a fresh, capped, polypropylene centrifuge tube. Twenty microliters of extraction buffer were added to the pelleted filter paper. After vortexing and centrifugation, the wash was collected and added to the first protein aliquot.
Protein concentration in impression cytology samples was determined using the DC Protein Assay Kit, and tear protein concentration was determined by Pierce Micro BCA assay (Pierce, Rockford, IL) following the manufacturer's instructions.
Mucin mRNA Quantitation
MUC1 and MUC16 mRNAs were assayed on reversetranscribed RNA isolated from the impression cytology samples using a real-time polymerase chain reaction, as previously described. 14 Briefly, complementary DNAwas reverse-transcribed from the RNA using random hexamer primers with Superscript III First-Strand Synthesis System for reverse-transcription polymerase chain reaction (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Relative expression of MUC1 and MUC16 was determined by multiplex real-time polymerase chain reaction using target (300 nM) and endogenous control (100 nM) oligonucleotide primers in the presence of gene-specific dyelabeled TaqMan probes (100 nM) and TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA). Primers and probes used were as published, 14 except with the addition of MUC1 forward, CTGGTCTGTGTTCTGGTTGC, and MUC1 reverse, CCACTGCTGGGTTTGTGTAA, and TaqMan probe, GAAAGAACTACGGGCAGCTG (Applied Biosystems). Data were collected on duplicate samples, and fold-expression changes were calculated using the comparative DDCt method as previously described. 15 
Protein Quantitation
Two types of assay [Western blot and enzyme-linked immunosorbent assay (ELISA)] were performed to optimize quantitation of multiple mucins from a single individual and to accommodate variable sample yield, which often precluded the ability to quantify all targets because of insufficient sample.
Western Blot
For assay of MUC1 and MUC16 proteins, proteins from tear washes (MUC1), capillary tears (MUC16), or isolated impression cytology samples (50 mg for MUC1; 10 mg for MUC16) were denatured in nonreducing Laemmli sample buffer, separated in a horizontal 1% (wt/vol) sodium dodecyl sulfate-agarose gel, and vacuum-transferred to nitrocellulose membrane for Western blot, as previously described. 3 Because of the large number of samples to be tested, each gel contained an aliquot of a single reference sample to normalize data between blots and allow semiquantitative comparisons of mucin levels. The reference sample for the Western blots was protein-isolated from an immortalized human corneal limbal epithelial cell line known to produce MUC1 and MUC16. 15 MUC1 protein content was detected with the MUC1-specific antibody 214D4 (Upstate Biotechnology, Inc., Lake Placid, NY) and MUC16 protein with the MUC16-specific antibody OC125 (Dako Carpinteria, CA). Detection of antibody binding was performed by reaction of blots with Pierce West Pico chemiluminescent substrate, followed by exposure to Hyperfilm ECL (Amersham, Buckinghamshire, UK). Densitometry was performed on blots photographed with a Kodak digital science camera, using ID Image Analysis Software, version 2.02 (Eastman Kodak, Rochester, NY), as described. 3 Data were normalized to the reference standard and expressed relative to the mean of the normal subjects.
Enzyme-Linked Immunosorbent Assay
For assay of MUC16 glycosylation, the H185 antibody, which recognizes a carbohydrate epitope on MUC16, [16] [17] [18] was used in an ELISA on proteins from tear wash (1 mg) and impression cytology samples (125 ng), as previously described. 18 MUC5AC content was determined on 0.5 mg of neuraminidase-treated protein from tear wash and impression cytology samples using the MUC5AC-specific antibody 791, as previously described. 6 Proteins pooled from multiple tear wash samples from a single individual were loaded in each ELISA plate as a standard reference to control for variation between assays. Data were normalized to the reference sample and expressed relative to the mean of the normal subjects.
Statistical Analysis
The range and mean values of each diagnostic test and the scores on the symptom and photophobia questionnaires were compared between the patients with dry eye and normal subject groups using Kruskal-Wallis tests in Instat3 statistical software (GraphPad Software, San Diego, CA). The statistical significance of differences in mucin mRNA and protein levels in dry eye compared with normal subjects was determined using the Mann-Whitney test. Correlations between mucin data and clinical parameters of all subjects, both normal subjects and patients with dry eye, were determined using the Spearman rank correlation test in Instat3.
RESULTS
Eighty-four postmenopausal women with dry eye were enrolled in this study, with selection based on the inclusion criteria of a recent diagnosis (signs and symptoms) of dry eye in addition to the need or desire to use artificial tears or lubricants. Thirty normal postmenopausal women without dry eye and not using artificial tears or lubricants were recruited as described in Materials and Methods.
Ranges and mean values of the diagnostic tests and the symptom and photophobia questionnaires are shown in Table 1 . Based on the general guidelines provided in the Dry Eye Workshop (DEWS) report, 1 all patients with dry eye were found to fall into the mild-to-moderate dry eye category. However, it is clear from the review of Table 1 that subjects not enrolled as having dry eye presented with some signs of dry eye but were not symptomatic based on the questionnaire scores. The comparison of subjects is based on the designation as symptomatic dry eye, as supported by a statistically significant difference in symptoms between the 2 groups as measured in symptom questionnaires and the need/desire of the patients with dry eye to use a dry eye treatment.
Tear wash samples harvested before impression cytology yielded 10 to 70 mL for normal subjects and 1 to 85 mL for patients with dry eye, with protein concentrations that ranged from 0.36 to 3.80 mg/mL (normal subjects) and 0.46 to 5.94 mg/mL (patients with dry eye). Preliminary studies were performed to compare the 2 tear collection techniques, and similar results were found for mucin quantification (data not shown), albeit tear wash collections yielded more protein than did capillary tear collection.
In some samples, there was insufficient protein to perform all mucin assays. The MUC1 assays require at least 5times the amount of protein than assays of the other mucins; thus, the number of data points for MUC1 tear assays was less (n = 16 for normal tear samples and n = 35 for dry eye tear samples) compared with that of other analyses.
Mucin Levels
For best accuracy of mucin mRNA and protein assays, assays that previously had been validated for quantitation of mucin gene expression and protein levels were used. 3, 6, 15 Any differences in starting amount of total RNA between samples was accounted for by normalization to expression of an endogenous control gene (GAPDH); for variation between immunoblots and ELISA, data were normalized to a mucin reference included in each assay. The amount of MUC1 mRNA and cellular protein from impression cytology samples of patients with dry eye was significantly higher relative to the normal subjects (Fig. 1A) . The amount of released MUC1 ectodomain in the tear washes did not, however, significantly differ between the 2 groups (Fig. 1A) .
Similarly, the amount of MUC16 cellular protein from impression cytology samples of patients with dry eye was significantly higher than that from normal subjects samples (Fig.  1B) . The MUC16 mRNA levels, although increased in dry eye samples compared with normal subjects, did not reach the level of significant difference. The amount of MUC16 ectodomain in tears, as with MUC1, did not differ between healthy and dry eye populations (Fig. 1B) . Binding of the H185 antibody, which recognizes an O-acetylated sialic acid epitope on MUC16, to proteins in tear washes from patients with dry eye was significantly increased over normal subject values, whereas no differences were found in binding in impression cytology samples (Fig. 1B) . In fact, a decrease, albeit not significant, was observed in amount of H185 binding to the cellular samples from patients with dry eye (Fig. 1B) . These data using the H185 antibody suggest that there is no change in glycosylation of MUC16 in the patients with dry eye.
The amount of goblet cell-derived MUC5AC in cellular or tear samples did not differ significantly between healthy and dry eye samples (Fig. 1C ). There was, however, a trend of increased cellular MUC5AC in these patients with mild-tomoderate stage dry eye.
Correlations Between Mucin Content and Dry Eye Diagnostic Tests
Clinical assay data obtained from both normal subjects and patients with dry eye at the time of sample collection were ranked and correlated with the mucin data. Correlations of mucin data with dry eye diagnostic test data are shown in Table 2 . A significant positive correlation between MUC1 expression and lissamine green staining and DESQ responses was found.
Similarly, MUC16 expression and protein levels showed several correlations to clinical parameters indicative of dry eye. MUC16 mRNA was negatively correlated with tear meniscus height. MUC16 cellular protein levels were positively correlated with multiple clinical data sets, including photophobia, sodium fluorescein (NaFl) staining, lissamine green staining, and scoring from the DESQ ( Table 2) . No correlations between H185 and clinical data were found. MUC5AC cellular protein negatively correlated with NaFl staining, whereas the amount of the MUC5AC in tears positively correlated with lissamine green staining.
DISCUSSION
Data from this study demonstrate an increase in expression of membrane-spanning mucins MUC1 and MUC16 in the ocular surface epithelia of postmenopausal women with a history of and symptomatology associated with mild-to-moderate non-Sjögren dry eye. The increase is documented by measurement of both RNA and protein levels. Although not enrolled on the basis of clinical signs as in previous studies, the subjects recruited for this study were derived from a relatively large study population (N = 84 patients with dry eye and N = 30 normal subjects) that demonstrated a mild correlation to several lines of clinical test results. The lack of clear clinical separation between the 2 groups in this study with respect to dry eye signs at the time of enrollment was not entirely surprising given the welldocumented lack of reliability between dry eye diagnostic tests and/or the disconnect between signs and symptoms of dry eye. 19, 20 It cannot be ruled out that some of the control ''normal'' subjects may have early dry eye without typical symptoms. However, the large population size, inclusion criteria, and demonstration of symptom separation between the 2 groups in this study all suggest a role for elevated mucin FIGURE 1. Quantitative results obtained for assay of mucin mRNA expression and cellular and tear wash mucin protein amount in normal subjects and patients with dry eye. Data are expressed relative to mean of the healthy control subjects and represent the mean 6 standard error of the mean. Significant differences between normal subjects and patients with dry eye are shown by an asterisk. P values are indicated on the graphs. A, MUC1 expression and protein levels in conjunctival cells and tear washes. B, MUC16 expression and protein levels and the amount of the terminal O-acetylated sialic acid epitope on MUC16 that is detected with the H185 antibody. C, MUC5AC cellular and tear wash protein. Sample sizes for all assays were N = 29 to 30 for normal subjects and N = 78 to 84 for patients with dry eye, except for the tear wash assays for MUC1 (n = 16 normal subjects; n = 35 patients with dry eye) and MUC16 (n = 26 normal subjects; n = 65 patients with dry eye). expression in postmenopausal women presenting with mildto-moderate symptoms of dry eye.
The increase in mucin levels associated with mild presentation of dry eye, associated more with symptoms as opposed to significant signs, may be a compensatory response to the irritation and early-stage inflammatory characteristic of the disease. Furthermore, image analysis of the amount of immunohistochemically localized MUC1 on impression cytology samples from patients with mild-to-moderate dry eye showed similar results in that an increase in the membrane mucin was observed in the mild disease state. 10 As in this study, MUC16 was shown to be upregulated in conjunctival epithelial samples from patients with atopic keratoconjunctivitis. 21 Recently, MUC16 expression has been shown to be upregulated by the secretory form of phospholipase A2 group 2a (sPLA2-IIA) in human conjunctival epithelial cells in vitro. 22 Levels of secretory form of phospholipase A2 group 2a, a normal component of tears, recently have been demonstrated to be increased in the tears of patients with dry eye. 23 This increase in secretory form of phospholipase A2 group 2a may be responsible for the increased expression of MUC16 in the conjunctival epithelium of patients with dry eye seen in our study.
In comparison, Caffery et al 14 did not detect an upregulation of MUC16 in a study of 25 KCS patients but did find an increased expression and protein levels of MUC16 ectodomain in tears of 25 patients with Sjögren dry eye. The KCS patients were recruited on the basis of symptoms (requiring at least 6 out of a possible 10) and signs (Schirmer score of #10 mm in 5 min). Without additional information, it is difficult to determine the clinical similarity in the KCS group studied by Caffery in comparison with the group in this work and, thus, it is difficult to explain the difference in MUC16 findings between the 2 studies.
The assays used in our study included both the assay of mucin mRNA and mucin protein levels in the cells of the conjunctiva and the amount of released mucin ectodomain protein in tears. As such, there is no direct measurement of mucin levels on the apical surfaces of the conjunctiva. It is difficult, therefore, to correlate findings of this study with those of previous work demonstrating a decrease in the amount of binding of the H185 antibody, which recognizes the H185 carbohydrate epitope on MUC16, to apical surfaces of conjunctival cells in patients with non-Sjögren dry eye. There was, in these studies, a correlation of decreased binding of H185 antibody to apical surfaces of the conjunctiva with severity of disease. 9 Perhaps the loss of MUC16 from small, discrete, apical areas on the ocular surface, as indicated by both rose bengal and lissamine green staining, is a local phenomenon that is not within the range of detection of the methods used in the current study. The fact that the stained areas in dry eye lack MUC16 or its glycans is suggested by a recent demonstration that abrogation of MUC16 expression or O-glycan expression in human corneal epithelium in vitro allows rose bengal entrance into the epithelium. 4, 5 Furthermore, inflammatory mediators present in tears of patients with dry eye, which include interferon-g, tumor necrosis factor-a, and matrix metalloproteinases 7 and 9, have been demonstrated to have the ability to induce MUC16 ectodomain release and, in the case of tumor necrosis factor-a, MUC1 ectodomain release as well. 24, 25 These inflammatory mediators may be released locally and induce small areas of dye penetrance through the release of the ectodomain of MUC16.
Data obtained in this study of mild-to-moderate postmenopausal women with non-Sjögren dry eye showed no significant differences in MUC5AC cellular protein or tear levels as compared with the control population. These data differ from the those in studies of patients with Sjögren dry eye in which a significant decrease in MUC5AC expression levels and tear protein levels was demonstrated. 6 The data also differ from those of Zhao et al, 7 who studied MUC5AC tear/cellular protein levels in patients with non-Sjögren dry eye, as determined by election of proteins from Schirmer strips that collect both tears and adherent conjunctival epithelial cells. The differences between the data reported herein may be because of the differences in severity of disease in the study populations or differences in the measurement protocols used by Zhao et al. 7 Goblet cell numbers have been demonstrated to be significantly decreased in non-Sjögren dry eye and in Sjögren dry eye 26 ; however, the patients in the study were reported to have moderate-to-severe disease. Perhaps changes in goblet cell numbers, and thus MUC5AC production, do not occur until the later stages of disease. Thus, the mild-tomoderate disease population in this study shows no significant difference in MUC5AC protein levels.
The level of mucins in subjects correlated with several lines of clinical test results, including surface staining and DESQ response. Of the clinical parameters examined, only dry eye symptom and photophobia questionnaires' results were significantly different between the normal subjects and patients with dry eye, which was supported by the inclusion criteria of use, or lack thereof, of artificial tears. Significant correlations were, however, found between the mucin assays and several of the clinical parameters when all the data were compared using the Spearman rank correlation test. For example, as scores for photophobia, NaFl, and lissamine green staining increased, so did the amount of MUC16 cellular protein. Conversely, as NaFl staining decreased, so did MUC5AC cellular protein. Further work is required to investigate whether quantitation of mucins would provide valuable insight and/or serve as an alternative sign to characterize dry eye severity and progression. In summary, data from this study of postmenopausal women symptomatic for mild-to-moderate dry eye demonstrate that there is an increase in expression and protein levels of the membrane mucins MUC1 and MUC16 and that this upregulation correlates positively with several diagnostic tests. The upregulation in expression of the mucins may be a compensatory response to repair local areas of mucin loss on apical surfaces because of the ectodomain release potentially induced by inflammatory mediators. 24 Additional studies are needed to gain insight into the association between mucin expression and dry eye, defined both by symptoms and by other diagnostic end points. Such information would provide useful guidance for pathophysiological mechanisms of dry eye and potential treatment modalities, including antiinflammatory agents and agents that influence mucin expression.
